Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | Zendy

Mark A. Socinski | Zendy; Robert M. Jotte | Zendy; Federico Cappuzzo | Zendy; F. Orlandi | Zendy; Daniil Stroyakovskiy | Zendy; Naoyuki Nogami | Zendy; Delvys RodríguezAbreu | Zendy; Denis MoroSibilot | Zendy; Christian A. Thomas | Zendy; Fabrice Barlési | Zendy; Gene Grant Finley | Zendy; Claudia Kelsch | Zendy; Anthony Lee | Zendy; Shelley Coleman | Zendy; Yu Deng | Zendy; Yijing Shen | Zendy; Marcin Kowanetz | Zendy; Ariel López-Chávez | Zendy; Alan Sandler | Zendy; Martin Reck | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Author(s) -

Mark A. Socinski,

Robert M. Jotte,

Federico Cappuzzo,

F. Orlandi,

Daniil Stroyakovskiy,

Naoyuki Nogami,

Delvys RodríguezAbreu,

Denis MoroSibilot,

Christian A. Thomas,

Fabrice Barlési,

Gene Grant Finley,

Claudia Kelsch,

Anthony Lee,

Shelley Coleman,

Yu Deng,

Yijing Shen,

Marcin Kowanetz,

Ariel López-Chávez,

Alan Sandler,

Martin Reck

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1716948

Subject(s) - atezolizumab , oncology , medicine , cancer , immunotherapy , nivolumab

The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research